Abstract | BACKGROUND: METHODS: Thirty-six hemodialysis patients with intact parathyroid hormone (i-PTH) > 31.8 pmol/L were divided into two groups. Eighteen patients (Group 1) were given once weekly alfacalcidol for 6 months. The starting dose was 3 µg, which was increased or decreased by 1 µg per week. Eighteen patients (Group 2) were given thrice weekly alfacalcidol for 6 months. The starting dose was 1 µg, which was increased or decreased by 0.5 µg per dose. The dose was increased or decreased according to serum-corrected calcium (CCa), phosphorus (P), and i-PTH. Serum-CCa and P were measured weekly, whereas serum i-PTH and alkaline phosphatase were determined every month. RESULTS: Intact-PTH reduced significantly (p < 0.001) from 86 ± 33.20 pmol/L to 31.04 ± 7.77 pmol/L and from 83.64 ± 32.12 pmol/L to 33.09 ± 11.37 pmol/L post-treatment in Groups 1 and 2, respectively. Fifty-six percent of the patients had i-PTH ≤ 31.8 pmol/L at the last observation. Serum alkaline phosphatase reduced significantly (p < 0.001) from 227.94 ± 129.86 IU/L to 163.17 ± 95.29 IU/L and from 285.39 ± 232.36 IU/L to 202.56 ± 165.84 IU/L post-treatment in Groups 1 and 2, respectively. There were no significant differences in serum levels of CCa, P, or their product. CONCLUSION: Intravenous alfacalcidol thrice or once weekly is safe and effectively reduced the levels of i-PTH in hemodialysis patients.
|
Authors | Eid Mohamed El-Shafey, Ali Eid Alsahow, Gamal Fathy El-Nagar, Amal Ezzat |
Journal | Renal failure
(Ren Fail)
Vol. 33
Issue 3
Pg. 329-33
( 2011)
ISSN: 1525-6049 [Electronic] England |
PMID | 21401359
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Bone Density Conservation Agents
- Hydroxycholecalciferols
- alfacalcidol
|
Topics |
- Adult
- Aged
- Bone Density Conservation Agents
(administration & dosage)
- Female
- Humans
- Hydroxycholecalciferols
(administration & dosage)
- Hyperparathyroidism, Secondary
(drug therapy, etiology)
- Infusions, Intravenous
- Kidney Failure, Chronic
(complications)
- Male
- Middle Aged
- Prospective Studies
- Renal Dialysis
|